ABOUT DATAMONITOR HEALTHCARE
- About the Cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the hypertension market
CHAPTER 2 CURRENT MARKET ASSESSMENTS
- Strategic scoping and focus
- Market definition for this report
- Antihypertensive drug classes
- Global overview
- Global: current market assessment
- National markets
- Leading global brands
- Market issues
- US: current market assessment
- Overview
- Market issues in the US
- Japan: current market assessment
- Overview
- Market issues in Japan
- European Union: current market assessment
- Overview
- Market issues in the EU5
CHAPTER 3 FORECAST ANALYSIS
- Assumptions and events
- Ongoing trends
- Trial results
- New product launches
- Patent expiries
- ARB patent expiries
- CCB patent expiries
- Beta-blocker patent expiries
- ACE inhibitor patent expiries
- Other patent expiries
- Additional indications
- Methodology
- Forecasts
CHAPTER 4 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Introduction
- Clinical trials
- Gaining novel additional indications
- Entry strategy
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Global hypertension market data
- Therapeutic classification
APPENDIX B
- Bibliography
- Report methodology
- General
- Japan sales data
- ATC codes
- Key opinion leaders
- About Datamonitor
- About Datamonitor Healthcare
- About the Cardiovascular Disease analysis team
- Disclaimer
- Glossary
List of Tables
- Table 1: Sales and growth for antihypertensive drug classes in the seven major markets, 2002-03
- Table 2: Annual sales growth of antihypertensive drug classes, 2000-03
- Table 3: Top 10 global antihypertensive brands, 2003
- Table 4: Hypertension patient potential forecast for the seven major markets (000s), 2002-15
- Table 5: List of compelling indications and the recommended treatment classes from the JNC 7 and BHS-IV guidelines
- Table 6: Current indications for ARBs in addition to hypertension
- Table 7: Top 10 global fixed-dose combination antihypertensive brands, 2003
- Table 8: US sales and growth of drug classes
- Table 9: Japan sales and growth of drug classes, 2000-03
- Table 10: EU5 sales and growth of drug classes, 2000-03
- Table 11: Summary of current generic substitution policies in the EU5
- Table 12: Patent expiry dates used in forecasting antihypertensive market
- Table 13: Comparison of olmesartan and eprosartan key metrics
- Table 14: Antihypertensive classifications
- Table 15: Historical global sales of antihypertensives by classification
List of Figures
- Figure 1: Sales and growth for antihypertensive drug classes in the seven major markets, 2002-03
- Figure 2: Global sales vales for the antihypertensive classes, 2000-03
- Figure 3: Global antihypertensive market sales 2000-03
- Figure 4: Average ex-manufacturer prices of the leading brands of each antihypertensive class across all country markets, 2000-03
- Figure 5: Share of antihypertensive market represented by each of the seven major markets in 2003
- Figure 6: Sales and growth for fixed-dose combination antihypertensives in the seven major markets, 2002-03
- Figure 7: Annual US sales of the antihypertensive drug classes, 2000-03
- Figure 8: Annual Japanese sales of the antihypertensive drug classes, 2000-03
- Figure 9: Annual EU5 sales of the antihypertensive drug classes, 2000-03
- Figure 10: Combination antihypertensive use in the major markets in 2003
- Figure 11: Example trial design
- Figure 12: Global sales for olmesartan and eprosartan across the seven major markets, 1999-2003
|
Related Report
|
View Cart
